Murphy & Mullick Capital Management’s Citius Pharmaceuticals CTXR Stock Holding History

Murphy & Mullick Capital Management’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$144	Hold	160	–	–	﹤0.01%	712
2025 Q4	$124	Hold	160	–	–	﹤0.01%	741
2025 Q3	$251	Hold	160	–	–	﹤0.01%	657
2025 Q2	$254	Hold	160	–	–	﹤0.01%	652
2025 Q1	$238	Hold	160	–	–	﹤0.01%	649
2024 Q4	$640	Buy	+160	New	+$1.08K	﹤0.01%	619

Other funds holding CTXR

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

AAG

Asset Advisory Group Kinnelon, New Jersey $229M AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Murphy & Mullick Capital Management's CTXR Position: Q1 2026 in Review

Murphy & Mullick Capital Management held its Citius Pharmaceuticals (CTXR) position steady in Q1 2026 at 160 shares worth $144. The position accounts for ﹤0.01% of the portfolio, ranked #712.

Murphy & Mullick Capital Management first reported a position in CTXR in Q4 2024 and has held it in 6 quarters since. The position peaked at $640 in Q4 2024. 38 funds tracked by Wall St. Rank hold CTXR as of Q1 2026.

Murphy & Mullick Capital Management held 160 shares of Citius Pharmaceuticals worth $144 as of Q1 2026.
Murphy & Mullick Capital Management left its Citius Pharmaceuticals share count unchanged in Q1 2026.
Citius Pharmaceuticals made up ﹤0.01% of Murphy & Mullick Capital Management's portfolio in Q1 2026, its #712 holding.
Murphy & Mullick Capital Management first reported a position in Citius Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
Murphy & Mullick Capital Management's Citius Pharmaceuticals position peaked at $640 in Q4 2024.
38 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q1 2026, filed 17 Apr 2026.